dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

MET

N-Ethyl-N-methyltryptamine

Methylethyltryptamine

Psychoactive Class

Psychedelic Hallucinogen

Chemical Class

Tryptamine

MET is a lesser-known synthetic psychedelic of the tryptamine class,citation needed structurally related to DMT.¹ It produces powerful, short-lived psychedelic effects characterized by rapid onset and progressive stages. When smoked or vaporized, its effects have been compared to those of DMT but with a more grounded headspace and reduced subjective intensity. Very little data exists regarding its pharmacology, metabolism, or toxicity, and it has only been available through online research chemical vendors since mid-2016.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~40 mg

Light60-120 mg

Moderate120-150 mg

Strong150-200 mg

Heavy200+ mg

Duration

Onset60-120 minutes

Come Up30-60 minutes

Peak1.5-2.5 hours

Offset1-3 hours

After Effects6-24 hours

Total4-6 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

MET produces a psychedelic tryptamine experience frequently compared to DMT, though gentler and more approachable — it has been described as a 'beginner DMT' and as combining qualities of DMT and Salvia divinorum. When vaporized, the onset is noticeably slower than that of DMT, building over a gradual come-up into a state that blends a slightly LSD-like psychedelic headspace with a warm, MDMA-like emotional core and mild stimulation. A deeply comfortable sense of body warmth is a distinctive feature of the experience.

Physical

The body load centers on a satisfying warmth and comfort accompanied by mild physical stimulation, though muscle tension, cramps, teeth grinding, sweating and chills, and restlessness are also reported. Route-specific discomforts include nasal pain when insufflating the freebase and an unpleasant taste and lung harshness when vaporized.

Cardiovascular

Increased heart rate Increased blood pressure

Stimulation

Uncomfortable

Muscle tension Muscle cramps Teeth grindingAppetite suppression Pupil dilation

Cognitive

The headspace is euphoric and empathogenic, with reports of insight, a softening of the ego, and a general change in perception. Confusion can occur, particularly at stronger doses.

Emotional

The emotional tone is warm and euphoric, with an empathogenic quality compared to MDMA.

Suppressions

Confusion

Visual

Open- and closed-eye visuals are among the most commonly cited effects, with a character often likened to a milder DMT.

Hallucinatory States

Tactile

Touch is noticeably enhanced, contributing to the characteristic sense of bodily warmth and comfort.

See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)

Pharmacology

Pharmacodynamics

MET acts principally as a partial agonist at serotonin 5-HT2Acitation needed and 5-HT2C receptors. It shows very weak agonist activity at 5-HT1A and 5-HT2B receptors. In addition to its action at serotonin receptors, MET functions as a serotonin releasing agent, though with comparatively lower potency.²

Pharmacokinetics

There have been no studies on the pharmacokinetic profile of MET and the metabolism of MET is unknown.

Metabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check

TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance

In contrast to most psychedelics, MET is not reported to produce tolerance easily. However, its extended residual effects suggest mild tolerance may occur when doses are taken close together.

Cross Tolerance

Reports indicate minimal, if any, cross-tolerance with other psychedelics, so other psychedelics would be expected to retain their full effects after MET use

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

Early reports characterize MET as non-habit-forming, with interest in taking it potentially declining after regular use. Like most psychedelics, it is generally viewed as self-limiting.

Toxicity

Lethal Dosage

The exact toxic dose is unknown, as the toxicity and long-term health effects of recreational MET use do not appear to have been studied in any scientific context. Anecdotal reports from the community suggest no negative health effects from trying the substance alone at low to moderate doses used sparingly, though nothing can be guaranteed.

History & Culture

MET was first documented in scientific literature in 1981, appearing in Michael Valentine Smith's book "Psychedelic Chemistry." The compound subsequently received a brief entry in Alexander Shulgin's 1997 publication "TiHKAL" (Tryptamines I Have Known and Loved)citation needed, though it did not…

Legality

By Country

Illegal3

New ZealandIllegal (analog/blanket ban)

SwitzerlandIllegal (analog/blanket ban)

Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (BetmVV-EDI; SR 812.121.11), consolidated version standing 13 March 2026, Article 1(2), Article 2(2) and Annex 6 Verzeichnis e no. 266 (Tryptamine); Betäubungsmittelkontrollverordnung (BetmKV; SR 812.121.1), Articles 3(2)(e), 5(2) and 11(1); Betäubungsmittelgesetz (BetmG; SR 812.121), Articles 7(1), 19a and 20(1)(c)-(2)^{159161718192021}

PubChem identifies MET as the unsubstituted N-methyl-N-ethyltryptamine identity, not 4-HO-MET or 4-AcO-MET. Although MET is absent as an individual name in the current consolidated schedule, Annex 6 Verzeichnis e no. 266 expressly and directly covers tryptamine derivatives whose side-chain nitrogen bears alkyl groups; MET has methyl and ethyl on that nitrogen. Verzeichnis e is the Article 7 presumed-narcotic-like raw-material/product category, not Verzeichnis d's separately designated prohibited category. The named Tryptamine rule's structural condition matches the MET structure. Industrial and scientific use are the express no. 266 exceptions; private use is expressly not exempted. BetmKV places Verzeichnis e under the control measures applicable to Verzeichnis-a narcotics and assigns operating permits to the EDI. BetmG Article 7 and Article 20(1)(c) supply the direct unauthorized-conduct route, including cultivation, manufacture, import/export, storage, use and placing on the market, with up to three years' imprisonment or a monetary penalty; Article 20(2) provides at least one year's imprisonment for qualifying commercial trade with large turnover or substantial profit. Article 19a provides a fine-based consumption provision; the cited provisions do not state a quantity-independent MET-specific charge, and Article 19(2)'s aggravated one-year minimum is not part of the Article 7/20 route. The consolidated BetmVV-EDI version is dated 13 March 2026; the BetmG version is dated 1 September 2023. The cited statutory scope does not establish product authorization, a specific quantity threshold, or blanket treatment for every possible MET form or preparation.

United KingdomClass A

Controlled / restricted2

GermanyNpSG (Controlled)

JapanControlled

Not scheduled1

United StatesNot scheduled

References

Source Pages

Citations

Article Status

Step 1 · Automated synthesis
An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest 31 Jul

Times are UTCNewest first

31 July 2026

15:14
Lyrea · Updated the article
15:12
Lyrea · Updated the article

13 July 2026

19:07
Lyrea · Updated the article

24 January 2026

23:32
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
23:25
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
23:20
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
23:15
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
22:57
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the MET article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.